trending Market Intelligence /marketintelligence/en/news-insights/trending/Fzk8oVu9eTg0Y0dsFBt6Dw2 content esgSubNav
In This List

Celgene to acquire biotech firm in $300M deal

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Celgene to acquire biotech firm in $300M deal

Celgene Corp. is set to acquire privately held biotechnology firm Delinia Inc. for an initial payment of $300 million.

Delinia's shareholders are eligible for an additional $475 million in contingent payments upon achievement of certain development, regulatory and commercial milestones.

The acquisition will expand Celgene's inflammation and immunology pipeline through Delinia's lead program, DEL106, a novel IL-2 mutein Fc fusion protein that helps in the restoration of the immune system.

The transaction is expected to close in the first quarter of 2017.